Ohana Aspires to Help People on Their Journey to Build a Family

Infertility rates are rising and have reached a 32-year high, yet current treatment methods leave many people out. Most couples undergo more than two rounds of IVF to achieve pregnancy, driving increased financial cost and emotional and physical burdens. It’s time to find a more effective solution.

In the U.S., more than seven million couples struggle with infertility annually, extending to tens of millions worldwide. Following a diagnosis of infertility, women can feel as anxious or depressed as those diagnosed with a life-threatening condition such as cancer or heart disease, while men experience similar feelings of low self-esteem, shame and depression.

People who experience challenges conceiving naturally sometimes turn to assisted reproductive technologies, or ARTs, to help them achieve their dream of having children. The two fertilization procedures most commonly used are in vitro fertilization (IVF) and intrauterine insemination (IUI).

However, depending on the factors influencing infertility, the live birth rates for each IVF cycle can be as low as 13% for women over 40 years old, and up to 43% for those under the age of 35. In the case of IUI, live birth rates per cycle are between 5% to 15%. These low success rates, coupled with the financial, physical and emotional burdens of treatment, weigh heavily on decisions to pursue treatment for fertility issues. Today, 90% of people struggling with fertility issues do not move forward with treatment.

Ohana’s Solution

Significantly Increase Live Birth Rates

Ohana’s investigational sperm treatments seek to mimic the physiological and functional modifications of sperm that the female reproductive tract normally induces during natural conception. These changes have the potential to increase the sperm’s ability to fertilize an egg and result in a higher quality embryo. By mimicking these changes in sperm that are being used for fertility treatments, we believe we can significantly increase the success rates of assisted reproductive technologies such as IVF, and thereby reduce the financial, physical, and emotional burden associated with fertility issues.

In preclinical mouse studies, the use of Ohana’s sperm enhancement treatment significantly increased the success rates of both IVF and IUI therapies. When used in conjunction with IVF, live birth rates increased by more than three-fold from the same number of embryos transferred using proprietary activated sperm versus the standard method of activating mouse sperm. When used during IUI, live birth rates increased by five-fold versus the standard IUI procedure in mice.

In studies performed on human sperm obtained from men in couples seeking treatment for infertility, Ohana’s sperm treatment increased the percentage of hyperactivated sperm from 7.5% to 17%, a level that has been historically associated with significantly improved pregnancy rates in IVF.